KR870007163A - 질소함유 융합 헤테로 사이클릭 화합물의 제조방법 - Google Patents

질소함유 융합 헤테로 사이클릭 화합물의 제조방법 Download PDF

Info

Publication number
KR870007163A
KR870007163A KR870000328A KR870000328A KR870007163A KR 870007163 A KR870007163 A KR 870007163A KR 870000328 A KR870000328 A KR 870000328A KR 870000328 A KR870000328 A KR 870000328A KR 870007163 A KR870007163 A KR 870007163A
Authority
KR
South Korea
Prior art keywords
compound
salt
prepared
structural formula
following structural
Prior art date
Application number
KR870000328A
Other languages
English (en)
Inventor
이꾸오 우에다
마사끼 마쓰오
기요시 쓰지
히로유끼 오쿠무라
오사무 나까구찌
Original Assignee
후지사와 도모기찌로
후지사와 야꾸힝 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 도모기찌로, 후지사와 야꾸힝 고교 가부시끼가이샤 filed Critical 후지사와 도모기찌로
Publication of KR870007163A publication Critical patent/KR870007163A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

내용 없음

Description

질소함유 융합 헤테로 사이클릭 화합물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 다음의 공정으로 다음 구조식을 갖는 화합물 또는 그 약학적으로 사용 가능한 염을 제조하는 방법 :
    상기 식에서.
    R1과 R2는 같거나 다르며, 각각 수소, 할로겐, 아릴, 저급알킬, 할로(저급)알킬 또는 니트로,
    R3는 저급알킬렌,
    R4와 R5는 같거나 다르며, 각각 저급알킬렌,
    X는 CH 또는 N,
    Y는 S,O,NH, C=N-OH 또는 CO,
    Z는 O 또는 NH이고,
    A는 수소, 니트로조, 아미디노, 다음의 기
    상기 식에서,
    R6과 R7은 같거나 다르며, 각각 수소, 저급알킬, 아실, 에스테르화 카르복시 치환 또는 비치환의 저급 알칸이미도일, 또는 다음의 기 : -N=R8
    상기 식에서,
    R8은 적절한 치환체(들)로 임의로 치환될 아릴로 치환할 수도 있는 저급알킬리덴이다.
    (1) 다음 구조식을 갖는 화합물이나
    그 카르복시기에서의 반응성 유도체 또는 그 염을, 다음 구조식을 갖는 화합물이나
    그 아미노기에서의 반응성 유도체, 또는 그 염과 반응시켜 다음 구조식을 갖는 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y,Z와 A는 전술된 바와 같다.
    (2) 다음 구조식을 갖는 화합물
    또는 그 염을 니트로조화 반응시켜 다음 구조식의 화합물,
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 각각 전술될 바와 같다.
    (3) 다음 구조식을 갖는 화합물
    또는 그 염을 환원시켜, 다음 구조식을 갖는 화합물,
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 전술된 바와 같다.
    (4) 다음 구조식을 갖는 화합물
    또는 그 염을 아실화하여,
    다음 구조식을 갖는 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 전술된 바와 같고, Ra 6은 아실이다.
    (5) 다음 구조식을 갖는 화합물
    또는 그 염을 알킬화시켜, 다음 구조식을 갖는 화합물,
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 각각 전술된 바와 같고, Rb 6은 저급알킬이고, Ra 7은 수소 혹은 저급알킬이다.
    (6) 다음 구조식을 갖는 화합물
    또는 그 염을, 다음 구조식을 갖는 화합물과 반응시켜
    R9-CHO
    다음 구조식을 갖는 화합물,
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 각각 전술된 바와 같고, R9는 수소, 저급알킬 또는 적절한 치환체(들)로 임의로 치환된 아릴이다.
    또는 그 염을 환원시켜, 다음 구조식을 갖는 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,R9,X,Y와 Z는 각각 전술된 바와 같다.
    (8) 다음 구조식을 갖는 화합물
    또는 그 염을 가수 분해시켜, 다음 구조식을 갖는 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 각각 전술된 바와 같고, R10은 아실, R11은 수소 또는 R10과 R11이 함께 결합하여 다음의 기를 형성한 것 :
    =R8상기 식에서 R8은 전술된 바와 같다.
    (9) 다음 구조식을 갖는 화합물
    또는 그 염을, 다음 구조식을 가진 화합물
    또는 그 염과 반응시켜 다음 구조식을 갖는 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 각각 전술된 바와 같고, R12는 저급알킬이고, R13은 에스테르화 카르복시이다.
    (10) 다음 구조식을 갖는 화합물
    또는 그 염을 환원시켜, 다음 구조식을 갖는 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,R12,R13,X,Y와 Z는 전술한 바와 같다.
    (11) 다음 구조식을 갖는 화합물
    또는 그 염을 다음 구조식을 갖는 화합물
    또는 그 염과 반응시켜,
    다음 구조식의 화합물
    또는 그 염을 제조한다.
    상기 식에서,
    R1,R2,R3,R4,R5,X,Y와 Z는 각각 전술된 바와 같고, R14는 저급알킬티오이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870000328A 1986-01-17 1987-01-17 질소함유 융합 헤테로 사이클릭 화합물의 제조방법 KR870007163A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8601160 1986-01-17
GB868601160A GB8601160D0 (en) 1986-01-17 1986-01-17 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
KR870007163A true KR870007163A (ko) 1987-08-17

Family

ID=10591560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870000328A KR870007163A (ko) 1986-01-17 1987-01-17 질소함유 융합 헤테로 사이클릭 화합물의 제조방법

Country Status (14)

Country Link
US (1) US4797399A (ko)
EP (1) EP0232740A1 (ko)
JP (1) JPS62181253A (ko)
KR (1) KR870007163A (ko)
CN (1) CN87100707A (ko)
AU (1) AU6762687A (ko)
DK (1) DK8687A (ko)
FI (1) FI865369A (ko)
GB (1) GB8601160D0 (ko)
IL (1) IL81172A0 (ko)
NO (1) NO870053L (ko)
OA (1) OA08462A (ko)
PT (1) PT84103A (ko)
ZA (1) ZA869748B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601366B1 (fr) * 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
GB8714596D0 (en) * 1987-06-22 1987-07-29 Fujisawa Pharmaceutical Co Thiazolopyridine compounds
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2669336B1 (fr) * 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602294D0 (en) * 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
DE19618999A1 (de) * 1996-05-10 1997-11-13 Klinge Co Chem Pharm Fab Neue Benzothiazolinone
DE19618970A1 (de) * 1996-05-10 1997-11-13 Klinge Co Chem Pharm Fab Neue Thiazolopyridine
PL331599A1 (en) * 1996-08-14 1999-08-02 Zeneca Ltd Substituted derivatives of pyrimidine and their pharmaceutical application
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
JP2001511798A (ja) 1997-02-13 2001-08-14 ゼネカ・リミテッド オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物
ATE242774T1 (de) 1997-02-13 2003-06-15 Astrazeneca Ab Heterozyklische verbindungen die als oxido- squalen-zyklase-inhibitoren anwendung finden
TW589309B (en) 1997-07-03 2004-06-01 Bristol Myers Squibb Pharma Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
US6355800B1 (en) * 1997-10-09 2002-03-12 Fujisawa Pharmaceutical Co., Ltd. Process for producing aminopiperazine derivatives
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
KR20060129023A (ko) * 2004-02-23 2006-12-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 헤테로환 화합물
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20060211685A1 (en) * 2005-03-04 2006-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MY151048A (en) * 2006-05-09 2014-03-31 Boehringer Ingelheim Int Use of flibanserin for the treatment of post-menopausal sexual desire disorders
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
AU2007286288A1 (en) * 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
US8686008B2 (en) * 2007-08-16 2014-04-01 The University Of Mississippi Highly selective sigma receptor ligands
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA928296A (en) * 1967-06-05 1973-06-12 Umio Suminori N-substituted and n, n-disubstituted aminocarbonylalkyl compounds and their production
GB1270841A (en) * 1969-03-28 1972-04-19 Fujisawa Pharmaceutical Co Benzothiazoline derivatives
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4279909A (en) * 1980-02-13 1981-07-21 Fujisawa Pharmaceutical Co., Ltd. Antiallergic method
JPS6015276A (ja) * 1983-07-04 1985-01-25 Nissan Motor Co Ltd 自動車組立工程における組付部品の仕様判別方法
JPS6063972A (ja) * 1983-09-17 1985-04-12 Sumitomo Electric Ind Ltd クライオスタツト

Also Published As

Publication number Publication date
DK8687A (da) 1987-07-18
NO870053L (no) 1987-07-20
DK8687D0 (da) 1987-01-08
NO870053D0 (no) 1987-01-06
PT84103A (en) 1987-02-01
IL81172A0 (en) 1987-08-31
EP0232740A1 (en) 1987-08-19
AU6762687A (en) 1987-07-23
OA08462A (fr) 1988-07-29
FI865369A0 (fi) 1986-12-31
GB8601160D0 (en) 1986-02-19
US4797399A (en) 1989-01-10
FI865369A (fi) 1987-07-18
JPS62181253A (ja) 1987-08-08
ZA869748B (en) 1987-08-26
CN87100707A (zh) 1987-09-02

Similar Documents

Publication Publication Date Title
KR870007163A (ko) 질소함유 융합 헤테로 사이클릭 화합물의 제조방법
KR840008016A (ko) 융합 이미다졸 화합물의 제조방법
KR840008333A (ko) 피리미딘 유도체의 제조방법
KR910004582A (ko) 티아졸 유도체, 이의 제조방법 및 이를 함유하는 약학조성물
KR870006072A (ko) 라파마이신 전구체의 제조방법
ES414279A1 (es) Procedimiento para la preparacion de 1,4-benzodiazepinas.
KR870003998A (ko) 퀴나졸린 유도체류의 제조방법
KR900009598A (ko) 혈관평활근 이완작용을 가진 화합물과 그의 제조방법
KR870006039A (ko) 신규 티아졸 화합물, 그 제조방법 및 이 화합물을 함유하는 약학적 조성물
AU7998291A (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ES8605511A1 (es) Un procedimiento para la preparacion de derivados de tiazol,2, 4, disustituidos.
KR870002078A (ko) 에틸렌디아민 모노아미드유도체의 제조방법
IE40409L (en) Novel 2,6- disubstituted phenyl-aminoguanidine compounds
ES8406193A1 (es) Procedimiento para la preparacion de nuevas 1,4-dihidropiridinas sustituidas
ES2021182A6 (es) Procedimiento para preparar derivados de capsaicina.
GB1425354A (en) Indole derivatives
DE69329385D1 (de) Thiazolin-derivate
KR860003259A (ko) 벤젠-융합 복소환 화합물의 제조방법
ATE78163T1 (de) Stickstoff enthaltende heterozyklische verbindungen.
KR830008998A (ko) N-치환된-아미노-아미노산의 제조방법
KR840006226A (ko) 티아트리아진 유도체의 제조방법
KR840006238A (ko) 신규 α-아릴-α-피리딜알카노인산 유도체의 제조방법
KR840001160A (ko) 벤조디옥산-이미다졸린 유도체의 제조방법
ATE78032T1 (de) 2-pyridylessigsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES8306099A1 (es) Un procedimiento para la preparacion de derivados de acido 2-(2-cianoetil)-2-benzoilamino-alcanoicos.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid